Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice
Developmental Cell · 2023-11 · 58 (21) · 2326-2337.e5
DOI: 10.1016/j.devcel.2023.09.007 ↗At a glance
Journal article in Developmental Cell, 2023-11. Written by Shuwei Hu and 19 co-authors. Institution: School of Basic Medical Sciences, Fudan University Shanghai, Shanghai 200032, China; Department of Integrative Medical Sciences, Northeast Ohio Medic…. Major MEDLINE topics: Lipoproteins, HDL, Atherosclerosis. Cited 22 times so far (Crossref); 44 references. Funded by: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.
Abstract (original language)
High-density lipoprotein (HDL) metabolism is regulated by complex interplay between the scavenger receptor group B type 1 (SR-BI) and multiple signaling molecules in the liver. Here, we show that lipocalin-2 (Lcn2) is a key regulator of hepatic SR-BI, HDL metabolism, and atherosclerosis. Overexpression of human Lcn2 in hepatocytes attenuates the development of atherosclerosis via SR-BI in western-diet-fed Ldlr-/- mice, whereas hepatocyte-specific ablation of Lcn2 has the opposite effect. Mechanistically, hepatocyte Lcn2 improves HDL metabolism and alleviates atherogenesis by blocking Nedd4-1-mediated SR-BI ubiquitination at K500 and K508. The Lcn2-improved HDL metabolism is abolished in mice with hepatocyte-specific Nedd4-1 or SR-BI deletion and in SR-BI (K500A/K508A) mutation mice. This study identifies a regulatory axis from Lcn2 to HDL via blocking Nedd4-1-mediated SR-BI ubiquitination and demonstrates that hepatocyte Lcn2 may be a promising target to improve HDL metabolism to treat atherosclerotic cardiovascular diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Basic Medical Sciences, Fudan University Shanghai, Shanghai 200032, China; Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
- Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
- Department of Pathology, School of Basic Medical Sciences, Fudan University Shanghai, Shanghai 200032, China.
- Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
- Department of Hepatobiliary Surgery, Peking University People's Hospital Xizhimen South Street, West District, Beijing 100044, China.
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210023, China.
Funding
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
Cite
APA
Hu, S., Zhu, Y., Zhao, X., Li, R., Shao, G., Gong, D., Hu, C., Liu, H., Xu, K., Liu, C., Xu, M., Zhao, Z., Li, T., Hu, Z., Shao, M., Liu, J., Li, X., Wu, H., Li, J., & Xu, Y. (2023). Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice. Developmental Cell, 58(21), 2326-2337.e5. https://doi.org/10.1016/j.devcel.2023.09.007
Vancouver
Hu S, Zhu Y, Zhao X, Li R, Shao G, Gong D, et al. Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice. Developmental Cell. 2023;58(21):2326-2337.e5. doi:10.1016/j.devcel.2023.09.007
BibTeX
@article{Hu2023,
author = {Hu, Shuwei and Zhu, Yingdong and Zhao, Xiaojie and Li, Rui and Shao, Guangze and Gong, Dongxu and Hu, Chencheng and Liu, Hongjun and Xu, Kexin and Liu, Chenxi and Xu, Minghuan and Zhao, Zhonghua and Li, Tao and Hu, Zhigang and Shao, Mengle and Liu, Jun- and Li, Xinwei and Wu, Huijuan and Li, Jing and Xu, Yanyong},
title = {Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice},
journal = {Developmental Cell},
year = {2023},
volume = {58},
number = {21},
pages = {2326--2337.e5},
doi = {10.1016/j.devcel.2023.09.007}
}
EUVIMED